Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 16/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604173 | 0.89 | MEN1 (0.63) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1604143 | 0.86 | HTR2B (0.69) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1920934 | 0.85 | HTR2B (0.68) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1604955 | 0.85 | HTR2B (0.70) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1604148 | 0.83 | HTR2B (0.70) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13060028 | 0.83 | MEN1 (0.66) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1605047 | 0.81 | HTR2B (0.66) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1604942 | 0.81 | HTR2B (0.72) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1604933 | 0.81 | HTR2B (0.65) | HTR2BMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13905660 | 0.81 | HTR2B (0.62) | HTR2BMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797099-B1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE INC (US) | 2010-08-11 | — | — | EP | claimed |
| CN-101048412-A | Piperidinylamino-thieno [2, 3-D ] pyrimidine compounds | EPIX DELAWARE INC (US) | 2007-10-03 | — | — | CN | claimed |
| EP-1797099-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | Epix Delaware, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | claimed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| EP-1797099-B1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE INC (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009032885-A2 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING FIBROSIS | EPIX DELAWARE, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| CN-101048412-A | Piperidinylamino-thieno [2, 3-D ] pyrimidine compounds | EPIX DELAWARE INC (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1797099-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | Epix Delaware, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | HTR2B 11/4885MEN1 2389/4885KMT2A 4258/4885 |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | HTR2B, HTR3B, HTR1B | HTR2B 1/4885MEN1 4118/4885KMT2A 3047/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | HTR2B 1/4885MEN1 4118/4885KMT2A 3047/4885 |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | HTR5A, HTR3A, HTR1A | HTR2B 10/4885MEN1 2784/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.